摘要
Background:Dupilumab is a recently developed fully human monoclonal antibody targeting the interleukin-4 receptor(IL-4R) α subunit,which blocks both interleukin-4(IL-4) and IL-13.Several clinical trials have demonstrated that Dupilumab treatment significantly alleviated the symptoms of atopic dermatitis(AD) without serious adverse effects.Objective:We sought to analyze the efficacy and safety of Dupilumab for the treatment of AD in a meta-analysis of clinical trial results.Methods:We searched the Pub Med,Medline,Embase,and Web of Science databases for suitable trials,and included only double-blind,randomized,placebo-controlled studies with Dupilumab-treated versus placebo-treated patients with AD.A systematic meta-analysis of randomized trials was performed to analyze the effect of Dupilumab on clinical indexes that correlated with the severity of AD and the safety profile of Dupilumab.Results:A total of five clinical trials were selected in our meta-analysis(N=587 adult participants,with moderate to se-vere AD).Among adult patients with moderate-to-severe atopic dermatitis,Dupilumab treatment yielded a significant improvement in clinical signs and symptoms of atopic dermatitis compared to placebo treatment.Furthermore,Dupilumab treatment did not show serious adverse effects as other systematic therapeutic drugs did,indicating that Dupilumab treatment is safe and well tolerated.Conclusion:Dupilumab is a promising therapeutic strategy that improves the management of adult patients with moderate to severe AD.
Background:Dupilumab is a recently developed fully human monoclonal antibody targeting the interleukin-4 receptor(IL-4R) α subunit,which blocks both interleukin-4(IL-4) and IL-13.Several clinical trials have demonstrated that Dupilumab treatment significantly alleviated the symptoms of atopic dermatitis(AD) without serious adverse effects.Objective:We sought to analyze the efficacy and safety of Dupilumab for the treatment of AD in a meta-analysis of clinical trial results.Methods:We searched the Pub Med,Medline,Embase,and Web of Science databases for suitable trials,and included only double-blind,randomized,placebo-controlled studies with Dupilumab-treated versus placebo-treated patients with AD.A systematic meta-analysis of randomized trials was performed to analyze the effect of Dupilumab on clinical indexes that correlated with the severity of AD and the safety profile of Dupilumab.Results:A total of five clinical trials were selected in our meta-analysis(N=587 adult participants,with moderate to se-vere AD).Among adult patients with moderate-to-severe atopic dermatitis,Dupilumab treatment yielded a significant improvement in clinical signs and symptoms of atopic dermatitis compared to placebo treatment.Furthermore,Dupilumab treatment did not show serious adverse effects as other systematic therapeutic drugs did,indicating that Dupilumab treatment is safe and well tolerated.Conclusion:Dupilumab is a promising therapeutic strategy that improves the management of adult patients with moderate to severe AD.
引文
